Pfizer and Allogene Therapeutics partner on immuno-oncology

Pfizer has signed a new asset contribution agreement with Allogene Therapeutics that will pool the companies' resources in the field of immuno-oncology.

The deal will see Allogene take responsibility for overseeing the development of Pfizer's portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer.

Pfizer will continue to support this drug development work by purchasing a 25 percent ownership stake in Allogene, while relying on the scientific, clinical development and regulatory expertise of Allogene's leadership team to drive the project forward.

Allogeneic CAR T cell therapies eliminate the need to create personalised therapies from a patient's own cells, instead allowing drugs to be developed from cells of healthy donors and stored for off-the-shelf use.

Robert Abraham, senior vice-president and group head of oncology research and development at Pfizer, said: "The allogeneic CAR T platform represents a potentially transformative approach to treating cancer, and we are very excited about what the future may hold for this area of research."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.